Lactic Acid Bacteria Improves Peyer's Patch Cell-Mediated Immunoglobulin A and Tight-Junction Expression in a Destructed Gut Microbial Environment

J Microbiol Biotechnol. 2016 Jun 28;26(6):1035-45. doi: 10.4014/jmb.1512.12002.


To evaluate the effects of lactic acid bacteria (LAB) on Peyer's patch cells, mice were treated with a high dose of kanamycin to disturb the gut microbial environment. The overarching goal was to explore the potential of LAB for use as a dietary probiotic that buffers the negative consequences of antibiotic treatment. In vitro, LAB stimulated the production of immunoglobulin A (IgA) from isolated Peyer's patch cells. Inflammation-related genes (TNF-α, IL-1β, and IL-8) were up-regulated in Caco-2 cells stimulated with lipopolysaccharide (LPS), while tight-junction-related genes (ZO-1 and occludin) were down-regulated; the effects of LPS on inflammatory gene and tight-junction gene expression were reversed by treatment with LAB. Mice treated with a high dose of kanamycin showed increased serum IgE levels and decreases in serum IgA and fecal IgA levels; the number of Peyer's patch cells decreased with kanamycin treatment. However, subsequent LAB treatment was effective in reducing the serum IgE level and recovering the serum IgA and fecal IgA levels, as well as the number of Peyer's patch cells. In addition, ZO-1 and occludin mRNA levels were up-regulated in the ileum tissues of mice receiving LAB treatment. Lactic acid bacteria can enhance the intestinal immune system by improving the integrity of the intestinal barrier and increasing the production of IgA in Peyer's patches. Lactic acid bacteria should be considered a potential probiotic candidate for improving intestinal immunity, particularly in mitigating the negative consequences of antibiotic use.

Keywords: Caco-2 cells; IgA; Lactic acid bacteria; Peyer's patch; kanamycin; tight junction.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects
  • Caco-2 Cells
  • Gastrointestinal Microbiome*
  • Humans
  • Immunoglobulin A / biosynthesis
  • Immunoglobulin A / blood
  • Immunoglobulin A / immunology
  • Immunoglobulin E / blood
  • Interleukin-1beta / genetics
  • Interleukin-8 / genetics
  • Kanamycin / administration & dosage
  • Kanamycin / adverse effects
  • Lactobacillus / physiology*
  • Lipopolysaccharides / pharmacology
  • Mice
  • Occludin / genetics
  • Peyer's Patches / cytology
  • Peyer's Patches / immunology*
  • Peyer's Patches / microbiology
  • Peyer's Patches / physiology*
  • Probiotics / therapeutic use*
  • Tight Junctions / genetics*
  • Tumor Necrosis Factor-alpha / genetics
  • Zonula Occludens-1 Protein / genetics


  • Anti-Bacterial Agents
  • Immunoglobulin A
  • Interleukin-1beta
  • Interleukin-8
  • Lipopolysaccharides
  • Occludin
  • Tjp1 protein, mouse
  • Tumor Necrosis Factor-alpha
  • Zonula Occludens-1 Protein
  • Immunoglobulin E
  • Kanamycin